Lung Cancer Dispatch
4.7K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer

ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

"ARIAD Pharmaceuticals, Inc. today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. These study results show anti-tumor activity of AP26113 in patients with crizotinib-resistant anaplastic lymphoma kinase (ALK) positive NSCLC, including patients with brain metastases. Crizotinib is approved for ALK-positive NSCLC patients."


Editor's note: This story is about a targeted drug called AP26113, which may benefit some patients with advanced non-small cell lung cancer (NSCLC). Specifically, it has shown promise for those patients whose tumors have mutations in the ALK gene, as detected by molecular testing, and who have already been treated with the drug crizotinib (Xalkori) but have grown resistant to it.

Cancer Commons's insight:

MarketWatch  |  May 31, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Promising Early Trial Results for New Lung Cancer Drug AP26113

An ongoing phase I/II clinical trial of the cancer drug AP26113 has produced encouraging preliminary results. The study examines patients with advanced non-small cell lung cancer (NSCLC) who have not responded, or have become resistant, to other treatments. AP26113 shrank tumors in the majority of patients with mutations in the ALK gene, including several whose cancer had spread to the brain. Effects were seen both in patients who had never been treated with the ALK inhibitor crizotinib (Xalkori) and patients who had become resistant to Xalkori. Preliminary evidence also suggests that AP26113 may be effective in patients with mutations in the EGFR gene who have become resistant to EGFR inhibitors like erlotinib (Tarceva) and gefitinib (Iressa). AP26113, which inhibits both ALK and EGFR, was well tolerated and serious side effects were rare. The trial is moving ahead into phase II based on these findings.

Cancer Commons's insight:

4-traders.com | June 2, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New ALK Inhibitor Shrinks Lung Cancer in Early Trial

New ALK Inhibitor Shrinks Lung Cancer in Early Trial | Lung Cancer Dispatch | Scoop.it

On the strength of promising results from an ongoing clinical trial, reseachers are starting a new trial for people with non-small cell lung cancer (NSCLC) that has abnormal ALK genes. This update was presented at the 2013 European Cancer Congress in Amsterdam, Netherlands. The phase I/II trial included 34 people with NSCLC with ALK abnormalities who were treated with an ALK inhibitor called AP26113. Tumors shrank in nearly all of the patients, including tumors that had spread to the brain, as well as those that resisted another ALK inhibitor called crizotinib (Xalkori). The new trial will test how well AP26113 shrinks NSCLCs that both have ALK abnormalities and are resistant to crizotinib.

Cancer Commons's insight:

ARIAD Pharmaceuticals, Inc. │Sep 28, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Drug Holds Promise for Patients with ALK Mutant NSCLC

New Drug Holds Promise for Patients with ALK Mutant NSCLC | Lung Cancer Dispatch | Scoop.it

Drug-maker Ariad Pharmaceuticals has announced promising initial results from an ongoing clinical trial investigating AP26113 in non-small cell lung cancer (NSCLC) patients. The pill demonstrates anti-tumor activity in patients who test positive for ALK mutation and may also be effective in patients with EGFR mutation. AP26113 has proven beneficial for some ALK+ patients with crizotinib resistance. These results were reported at the annual congress of the European Society for Medical Oncology (ESMO) in Vienna, Austria.

Cancer Commons's insight:

PMLiVE | Oct 2, 2012

more...
No comment yet.